By: Chendong Ma, Gangwei Zhou, Si Wan, Jiaru Jiang, Fei Shen, Sicong Jiang, Qunchao Zhu
Keywords: Ambroxol; Aminophylline; Acute exacerbation period; Chronic obstructive pulmonary disease; Clinical efficacy; Doxophylline
DOI : 10.36721/PJPS.2026.39.3.REG.14753.1
Abstract: Background: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) manifests as sudden respiratory symptom aggravation and airflow decline, substantially elevating mortality risk, making therapeutic optimization crucial for patient outcomes. Objectives: To compare the clinical efficacy and safety of the combination therapy of Doxophylline ambroxol and Aminophylline monotherapy in the treatment of AECOPD. Methods: This retrospective study included 120 AECOPD patients admitted from April 2022 to April 2024. Patients were divided into two groups: the control group received aminophylline, while the study group received doxophylline and ambroxol for 10 days. Clinical efficacy, pulmonary function (FEV1, FVC, FEV1%, FEV1/FVC), inflammatory markers (CRP, PCT, WBC, NEUT%), blood gas parameters (PaO2, PaCO2), CAT and CCQ scores and adverse events were compared pre- and post-treatment. Results: Post-treatment, both groups showed significant improvements in FEV1, FVC, FEV1% and FEV1/FVC compared to baseline (P<0.05), with the study group demonstrating superior outcomes (P<0.05). Inflammatory markers (CRP, PCT, WBC, NEUT%) decreased significantly in both groups, with greater reductions in the study group (P<0.05). Blood gas parameters (PaO2, PaCO2) improved in both groups (P<0.05), with more pronounced improvements in the study group (P<0.05). CAT and CCQ scores declined in both groups, but more substantially in the study group (P<0.05). No significant difference in adverse events was observed (P>0.05). Conclusion: Doxophylline-ambroxol combination therapy is more effective than aminophylline in improving pulmonary function and reducing inflammation in AECOPD, with equivalent safety.
[View Complete Article]
